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Bloodstream infections in patients 
living with HIV in the modern cARt 
era
L. taramasso  1,2, F. Liggieri1, G. Cenderello3, F. Bovis4, B. Giannini5, A. Mesini1, M. Giacomini  5, 
G. Cassola3, C. Viscoli1 & A. Di Biagio6
Retrospective multicentre study aiming at analysing the etiology, characteristics and outcome of 
bloodstream infections (BsI) in people living with HIV (pLWHIV) in an era of modern antiretroviral 
therapy. Between 2008 and 2015, 79 PLWHIV had at least 1 BSI, for a total of 119 pathogens isolated. 
Patients were mainly male (72.1%), previous intravenous drug users (55.7%), co-infected with HCV or 
HBV (58.2%) and in CDC stage C (60.8%). Gram-positive (G+) pathogens caused 44.5% of BSI, followed 
by Gram-negative (G−), 40.3%, fungi, 10.9%, and mycobacteria, 4.2%. Candida spp. and coagulase-
negative staphylococci were the most frequent pathogens found in nosocomial BSI (17% each), while 
E.coli was prevalent in community-acquired BSI (25%). At the last available follow-up, (mean 3.2 ± 2.7 
years) the overall crude mortality was 40.5%. Factors associated with mortality in the final multivariate 
analysis were older age, (p = 0.02; HR 3.8, 95%CI 1.2–11.7) CDC stage C (p = 0.02; HR 3.3, 95%CI 
1.2–9.1), malignancies, (p = 0.004; HR 3.2, 95%CI 1.4–7.0) and end stage liver disease (p = 0.006; HR 
3.4, 95%CI 1.4–8.0). In conclusion, the study found high mortality following BSI in PLWHIV. Older 
age, neoplastic comorbidities, end stage liver disease and advanced HIV stage were the main factors 
correlated to mortality.
Due to the availability of modern combined antiretroviral therapy (cART), patients living with HIV (PLWHIV) 
have experienced a reduction in overall mortality and incidence of AIDS-defining conditions1,2. The natural his-
tory of HIV infection has changed, evolving from a disease with a bad short-term prognosis to a long-term 
chronic infection, forcing physicians to focus on new clinical problems, such as aging, kidney disease, osteopo-
rosis, diabetes, cardiovascular diseases and the effects of long-term drug exposure. Indeed, late complications 
in otherwise responding HIV-infected patients exist and include, among others, neoplastic diseases requiring 
chemotherapy, putting these patients at risk of opportunistic infections similar to those encountered in the 
non-HIV positive population with the same cancer. In the meantime, in some countries, including Italy, up to 
29% of the patients arrive late at a HIV diagnosis, with CD4+ T-cell (CD4+) count <200/mmc or with an 
AIDS-defining condition (infection and/or cancer) already present at the moment of diagnosis3. In this patient 
population, the immunological recovery can be challenging4,5, and they may require long hospitalization for the 
combined treatment of the HIV infection, AIDS-related infections and sometimes neoplastic diseases6. At this 
point, they are at risk of developing classic healthcare-associated infections, such as bacteremia, which further 
complicate an already difficult situation. Indeed, non-AIDS defining bacterial infections are among the main 
causes of hospital admissions nowadays7–10.
The aim of the present study is to analyze the etiology, clinical characteristics and outcome of bloodstream 
infections (BSI) in PLWHIV in an era of cART in a country with a high rate of late-presenters.
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Results
Throughout the study period, 2379 PLWHIV were followed in the 2 participating centers with 2281 hospitali-
zations. A total of 79/2379 (3.3%) patients had at least 1 BSI, for a total of 104 episodes (67, 64.4%, community 
acquired and 37, 35.5%, hospital-acquired, Fig. 1) and 119 isolated pathogens. BSI accounted for or complicated 
a total of 93 of 2281 hospitalizations (4.0%), with a median duration of hospital stay of 17 (10–36) and 59 (31.5–
100.5) days in community-acquired and nosocomial episodes, respectively (p < 0.0001).
The majority of PLWHIV with BSI were male (72.1%), previous intravenous drug users (55.7%), co-infected 
with HCV or HBV (58.2%) and in CDC stage C (60.8%). General characteristics of the study population are given 
in Table 1. The mean follow-up period after the first BSI episode was 3.2 ± 2.7 years.
The median CD4+ count at first BSI was 175 (88–331.5) cells/μl as compared to 420 (252–610) in the general 
population of PLWHIV observed at the first visit to the 2 outpatient clinics during the study period (p < 0.0001). 
Among patients with at least 1 BSI, the proportion of late-presenters was 24.0% (19 of 79) as opposed to 10.4% 
(239 of 2304) in the group of patients without any BSI (p < 0.0001).
Figure 1. Number of community acquired and nosocomial episodes of bloodstream infections (BSI) and 
CD4+ T-lymphocytes (CD4) count in the whole study population (a) and in patients newly diagnosed with 
HIV (b) in the years of the study. P values in the graph are referred to the CD4 trend across the study period.
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A total of 14 patients developed more than 1 BSI episode. They had similar characteristics as compared with 
patients with a single episode (i.e., age, sex, CDC stage, frequency of HBV and HCV co-infection and of late pres-
entation, CD4+ count and nadir at the time of the first BSI).
Among the 119 isolated pathogens, there were 53 (44.5%) Gram-positive (G+) cocci, 48 (40.3%) 
Gram-negative (G−) rods, 13 (10.9%) fungi (9 candidemia and 4 cryptococcal infections) and 5 (4.2%) myco-
bacteria (2 M. tuberculosis complex and 3 M. avium complex). Candidemia was caused by C. albicans in 6/9 cases, 
C. glabrata, C. tropicalis and C. parapsilosis in 1/6 cases each. The median CD4+ T-cell count (cells/μl) was 210 
(102–299.5) in patients who developed a BSI caused by G−, 132 (60–250) in G+, 77 (11.5–120) in mycobacteria 
and 62 (35–215) in fungal BSI, with a significant decreasing trend in the different groups of etiologies (p = 0.011). 
Parallelly, the frequency of late presenting in each group of etiologies was also different, higher in mycobacterial 
(80.0%) than in fungal (53.8%), G+ (24.5%) and G− (14.6) BSI, p < 0.0001.
In Table 2, all pathogens are classified, whether isolated in nosocomial or community-acquired episodes. 
As expected, Candida spp. and coagulase-negative staphylococci (CONs) were more often nosocomial in ori-
gin (8 of 9 each), while E.coli was prevalent in community-acquired BSI (18 episodes, 24.6%). With respect to 
community-acquired episodes, nosocomial BSI were more often observed in patients on antiretroviral treatment 
and with BSI caused by Candida spp. On the other side, hospitalization for an acute infectious disease or febrile 
Age, median (1st–3rd quartile) 47 (20–78)
Gender (Male), n (%) 57 (72.1)
HBV/HCV coinfection, n (%) 46 (58.2)
Last CD4 < 100 N/mmc, n (%) 24 (30.4)
Last CD4 < 200 N/mmc, n (%) 45 (56.9)
Late Presenter, n (%) 19 (24.0)
On co-trimoxazole prophylaxis, n (%) 21 (26.6)
On antiretroviral treatment, n (%) 52 (65.8)
- NRTI + NNRTI 6 (11.5)
- NRTI + PI 31 (59.6)
- NRTI + INSTI 9 (17.4)
- Other regimens 6 (11.5)
HIV-RNA ≥ 200 copies/ml, n (%) 48 (60.7)
Detectable HIV-RNA despite antiretroviral 
treatment, n (%) 21 (26.6)
Patients with at least one N-BSI, n (%) 27 (34.2)
Patients with at least one CA-BSI, n (%) 57 (72.1)
Patients with both N- and CA-BSI, n (%) 4 (5.1)
Patients with more than one episode of BSI, n (%) 14 (17.7)
CDC stage B, n (%) 28 (35.4)
CDC stage C, n (%) 48 (60.8)
Route of transmission
Vertical, n (%) 4 (5.1)
Drug addiction, n (%) 44 (55.7)
Sexual, n (%) 31 (39.2)
Comorbidities
HBV/HCV co-infection, n (%) 46 (58.2)
- Cirrhosis, n (%) 26 (32.9)
- End stage liver disease, n (%) 9 (11.4)
- HCC, n (%) 1 (1.3)
Malignancies, n (%) 14 (17.7)
- Solid cancer, n (%) 7 (8.9)
- Lymphoma, n (%) 6 (7.6)
- Leukimia, n (%) 1 (1.3)
Psychiatric disorders, n (%) 5 (6.3)
Encephalopathies, n (%) 14 (17.7)
Diabetes, n (%) 7 (8.9)
Chronic kidney disease, n (%) 9 (11.4)
Current IVDU, n (%) 23 (29.1)
Table 1. General characteristics of the study population at time of first bloodstream infection (79 patients). 
NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: 
protease inhibitors; INSTI: Integrase strand transfer inhibitors; N-BSI: nosocomial bloodstream infection; CA-
BSI: community-acquired bloodstream infection; HCC: hepatocellular carcinoma; IVDU: intravenous drug use.
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syndrome was protective towards nosocomial episodes, compared to other causes of hospitalization (area under 
the curve of the model, AUC = 0.855, Table 3).
In terms of antimicrobial susceptibility, no G− rod was resistant to carbapenems, while 8 out of 37 
Enterobacteriaceae and 0 of 9 Pseudomonas spp. were ESBL-producers. Among G+ cocci, 7 out of 9 CONs (7/7 
nosocomial) and 8 of 14 S. aureus strains (3/8 nosocomial) were resistant to methicillin, while 9 of 11 enterococci 
were resistant to ampicillin. All but one G+ (i.e., one nosocomial-acquired E. faecium) were susceptible to van-
comycin. Two of 9 candidemias were due to fluconazole resistant strains (one C. albicans and one C. glabrata).
The observational analysis showed that the crude mortality after the first BSI episode in the 79 patients was 
6.3%; 8.9%, 21.5% and 27.8% at 2, 4, 24 and 48 weeks, while the overall mortality at the last available follow up was 
40.5%, (32/79 patients), with a median time between infection and death of 231 days (48–438). Four factors were 
associated with mortality at multivariable analysis: age >43 years (p = 0.02; HR 3.8, 95%CI 1.2–11.7), CDC stage 
C (p = 0.02; HR 3.3, 95%CI 1.2–9.1), malignancies (p = 0.004; HR 3.2, 95%CI 1.4–7.0), and end stage liver disease 
(p = 0.006; HR 3.4, 95%CI 1.4–8.0) (Table 4).
Discussion
In the present study, we analyzed the etiology and outcome of BSI in PLWHIV in the years 2008 to 2015 at two 
Infectious Disease Centers in Northern Italy. Despite the fact that the study has been conducted in the context of 
a modern cART era, only 66% of the patients were actually on antiretroviral treatment, and a high number of late 
presenters (24%) and patients in advanced stage of disease (61% in CDC stage C) were still present in our series. 
The patients who developed BSI had lower CD4+ counts and higher frequency of late presenters when compared 
to the global population of PLWHIV without BSI, confirming the importance of immune recovery for also pre-
venting bacterial infections other than those commonly codified as AIDS-defining11. Indeed, we found a quite 
high crude mortality rate in the first weeks after BSI, with a continuous increasing trend in the months following 
the episode, arriving to 40% after a median time of 231 days. This high mortality rate likely reflects the severity 
of the underlying diseases of patients who develop BSI and the high frequency of comorbidities in PLWHIV, 
possibly favored by a somewhat inadequate immunological reconstitution and by chronic immune activation12. 
This is shown by the fact that patients with BSI had lower CD4+ counts than the general population of PLWHIV 
and that, among them, mortality was higher in those with older age, more advanced CDC stage and comorbid-
ities such as malignancies or end stage liver disease. Surprisingly, we did not find a reduced HR for mortality in 
patients on cART, whether they had HIV-RNA < 200 copies/ml or not. However, cART is expected to diminish 
the risk of comorbidities found to be associated with higher mortality in our series, such as neoplastic diseases or 
AIDS-defining illnesses13, so that it is possible that the lack of association between cART use and reduced mortal-
ity might be simply due to the small sample size.
On the other hand, the high frequency of nosocomial episodes found suggests how BSI can also complicate 
the clinical course in otherwise responding HIV-infected patients, as these episodes were not linked to the CDC 
stage of disease but on the contrary more frequent in patients taking antiretroviral treatment who were mainly 
hospitalized for non-infectious illnesses.
The use of a modern cART might however have played a role in the general study population, as we found that 
the epidemiology of pathogens causing BSI changed with respect to previous data14–24. In fact, we found a high 
prevalence of G− as the cause of community-acquired BSI, with E. coli as the main causative agent overall. Even 
if an increasing prevalence of this pathogen had already been signaled in PLWHIV15, in our knowledge, it was the 
principal etiology of all BSI only in one previous study24,25. This change may be linked to easier and earlier access 
Pathogen Total C A N
Escherichia coli 20 18 2
Staphylococcus aureus 14 8 6
Other Streptococcus spp 12 9 3
Enterococcus spp 11 6 5
Candida spp 9 1 8
CONs 9 1 8
Pseudomonas spp 9 4 5
Klebsiella pneumoniae 8 4 4
Streptococcus pneumoniae 5 5 0
Mycobacteria spp 5 5 0
Cryptococcus neoformans 4 3 1
Salmonella spp 2 2 0
Serratia spp 2 2 0
Other G− 7 3 4
Other G+ 2 2 0
Total 119 73 46
Table 2. Number, type and distribution of 119 BSI causative agents. CA: community acquired; N: nosocomial; 
CONs: Coagulase-Negative Staphylococci; G−: Gram negative; G+: Gram positive.
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to cART in comparison with the past, with consequent decreasing frequency of “AIDS-defining BSI” and increase 
of other common causes of BSI, shared with HIV-negative patients26.
Less data is available on the etiology of hospital-acquired BSI in PLWHIV14,16,27–29. Candidemia had previously 
been reported as an emergent cause of BSI in PLWHIV25, but its burden seemed still higher in our work, where it 
was the first cause of nosocomial BSI and significantly correlated with the nosocomial occurrence of the infection. 
A possible interpretation is that the better survival of PLWHIV is burdened by longer and more frequent hospital-
izations, and this constitutes a well-known risk factor for the development of candidemia30. Indeed, nosocomial 
BSI in PLWHIV has increased in last years14,31 and constitutes about 35% of the episodes in our work.
Finally, we also assessed the resistance profile of principal G−, G+ and Candida spp. isolated from blood 
cultures. Despite the fact that resistance to carbapenems is a major concern in Italy, even with increasing 
rates in last years32, it did not have a major impact in PLWHIV during the study period, as no G− harbored 
carbapenem-resistant rods. Moreover, the majority of Enterobacteriaceae were susceptible to third generation 
cephalosporins, also if some ESBL producer strains were found. Numbers are too low to draw any conclusions, 
but on the basis of the descriptive analysis of our population, we can only say that the rising resistance reported in 
other contexts33 seem not to spare PLWHIV. The same is true also for G+. In fact, we found a quite high propor-
tion of community acquired methicillin resistant S. aureus, in accordance with the literature data34, while among 
CONs methicillin resistance was confined to nosocomial episodes. A single vancomycin resistant E. faecium was 
isolated, while all other G+ conserved vancomycin susceptibility.
The study has several limitations. A major limit is that we did not have a control group, so we could not 
demonstrate that the mortality we found, although unusually high, was significantly different from the mortal-
ity in PLWHIV without BSI with similar clinical conditions. Moreover, the retrospective design did not permit 
the analysis of all underlying conditions and concomitant therapies that may have influenced both the primary 
and secondary outcomes of the study. For the same reason, we cannot exclude an underestimation of the real 
number of BSI, as it is possible that in some cases either the blood cultures were not promptly collected or early 
antimicrobial treatment gave negative results before hospital admission or blood collection. In addition, changes 
Variable
Beta 
Estimate 95%CI p-value
Multivariate
Beta Estimate
Multivariate 
95%CI
Multivariate
p-value
Age < 47 years* 0.6 0.2–1.4 0.22
CD4 < 200 1.0 0.4–3.9 0.97
Decease at last follow up 0.8 0.3–1.9 0.56
End stage liver disease 0.8 0.3–2.0 0.59
G− 1.6 0.7–3.9 0.30
G+ 1.2 0.5–2.7 0.62
Fungi 3.8 1.3–10.8 0.01
Candida spp. 4.9 1.7–14.5 0.003 18.1 1.7–186.8 0.01
HIVRNA ≥ 200 cp/ml 1.5 0.5–4.3 0.41
Active IVDU 1.7 0.6–4.5 0.28
Late presentation 1.1 0.6–2.2 0.68
Male gender 1.1 0.4–3.2 0.80
On cART 3.3 1.3–8.0 0.009 4.1 1.3–13.1 0.02
N of previous infections 1.7 0.4–7.9 0.51
Co-trimoxazole prophylaxis 1.1 0.4–3.3 0.82
CDC stage C 0.9 0.3–2.2 0.75
Risk factor for HIV infection
IVDU 1.1 0.4–2.9 0.78
Vertical transmission 1.2 0.2–6.7 0.85
Sexual 0.8 0.3–2.2 0.73
Comorbidities
malignancies 1.3 0.5–2.9 0.59
Chronic kidney disease 0.2 0.02–2.1 0.20
HCV/HBV co-infection 1.2 0.5–3.1 0.68
Cirrhosis 1.8 0.7–4.5 0.22
Other comorbidities 0.9 0.3–2.4 0.78
Admitting dianosis
Sepsis 0.1263 0.02–0.5 0.005
Acute infectious disease or fever 0.0929 0.03–0.2 <0.0001 0.06 0.02–0.2 <0.0001
Table 3. Comparison of factors associated with nosocomial vs. community acquired BSI in 79 patients (119 
infections). Area under the curve of the multivariate model (AUC) = 0.855. CI: confidence interval; N: number; 
cp: copies; G+: Gram positive; G−: Gram negative; cART: combined antiretroviral therapy; IVDU: intravenous 
drug use. *dichotomized as per ROC.
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in infection-control practices or in the distribution of pathogens over time in the participating centers may have 
played a role in the epidemiologic framework described in the article that appeared different from those previ-
ously described in other similar studies13–23. Finally, the relatively low incidence of BSI in PLWHIV did not permit 
the analysis of a large amount of data, and fortuity may have played a role in the definition of some variables or in 
the lack of significance of others.
With these limitations, our study highlights new emerging features of BSI in PLWHIV in the recent cART 
era. BSI share the etiologies of both community-acquired and nosocomial episodes with HIV-negative patients 
but are still marked by high mortality, correlated not only to an advanced HIV stage but also to other major 
comorbidities. In the future, we expect that the scenario will change again as in the present study the history of 
intravenous drug use, now a declining risk factor, and HCV co-infection, now present only in a minority of new 
HIV diagnosis, are still highly represented35,36. Moreover, there are still numerous patients with low CD4+ counts 
HR (95% CI)
univariate p-value
HR (95% CI) 
multivariate p-value
Age 1.035 (1.003–1.068) 0.03
Age > 43* 4.0 (1.4–11.5) 0.009 3.8 (1.2–11.7) 0.02
Gender (Male) 1.5 (0.7–3.5) 0.33
HBV/HCV co-infection 1.8 (0.8–4.0) 0.13
Last CD4 < 200 N/mmc 1.6 (0.8–3.2) 0.22
HIVRNA ≥ 200 copies/ml 0.7 (0.3–1.4) 0.31
Nr of previous infections 1.3 (1.0–1.6) 0.02
CDC stage C 3.4 (1.4–8.3) 0.008 3.3 (1.2–9.1) 0.02
Etiology
- Fungi 3.5 (1.3–9.1) 0.01
- Gram+ 0.8 (0.4–1.7) 0.67
- Gram− 0.8 (0.4–1.7) 0.63
- Mycobacteria 0.5 (0.1–3.9) 0.54
Route of transmission
- Vertical 1.3 (0.3–5.5) 0.72
- Drug addiction 1.5 (0.7–3.1) 0.24
- Sexual 0.6 (0.3–1.3) 0.18
Nosocomial 1.4 (0.7–2.9) 0.33
Resistance to Beta-lactams** 1.8 (0.8–4.1) 0.18
Late Presentation 0.8 (0.3–2.1) 0.69
Comorbidities
-HBV/HCV co-infection 1.8 (0.8–4.0) 0.13
   - Cirrhosis 1.7 (0.8–3.3) 0.16
   - End stage liver disease 3.9 (1.8–8.5) 0.0006 3.4 (1.4–8.0) 0.006
- Malignancy 3.3 (1.6–6.8) 0.001 3.2(1.4–7.0) 0.004
- Chronic kidney disease 2.3 (0.9–5.6) 0.07
- Other comorbidities 1.3 (0.6–2.6) 0.48
Current IVDU 1.4 (0.7–3.0) 0.37
Cotrimoxazole prophylaxis 2.1 (1.1–4.3) 0.03
Not on cART 1
0.79On cART, HIV-RNA ≥ 200 copies/ml 1.0 (0.4–2.6)
On cART, HIV-RNA < 200 copies/ml 1.3 (0.5–3.0)
Admission diagnosis of infectious disease or fever 0.5 (0.3–1.1) 0.09
Admission diagnosis of Sepsis 1.9 (0.4–7.9 0.40
Table 4. Univariate and multivariate predictors of event (mortality at the last follow-up) in 79 patients. The 
multivariate analysis was performed on 77 patients with fully available data. *Dichotomized as per ROC. 
**Calculated for 70 patients with bacterial bloodstream infections. Results were interpreted in accordance with 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. Staphylococci 
were considered resistant if they were not susceptible to methicillin; Streptococci were considered resistant if 
they were not susceptible to amoxicillin; Enterococci were considered resistant if they were not susceptible to 
ampicillin; Gram negative bacteria were considered resistant if they were not susceptible to third generation 
cephalosporins or piperacillin/tazobactam. HR: Hazard Ratio; IVDU: intravenous drug use; cART: combined 
antiretroviral therapy. Admission diagnoses were referred to last hospitalization for patients with multiple 
episodes. Other comorbidities comprise: any encephalopathies (14 patients), diabetes (7 patients), psychiatric 
disorders (5 patients) and Chronic Obstructive Pulmonary Disease (3 patients). Malignancies comprise solid 
cancers and hematological malignancies.
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and with advanced diseases. Both hopefully will reduce in the next years due to new and earlier cART strategies. 
Multicenter and prospective studies in the future might better define BSI epidemiological changes, risk factors 
and outcomes in the continually evolving population of PLWHIV.
Methods
This is a retrospective study conducted in the period 2008–2015 at two Infectious Diseases Units in the city of 
Genoa (Italy, Liguria Region), the Ospedale Policlinico San Martino and the Ente Ospedaliero Ospedali Galliera. 
The 2 units follow slightly more than 2000 HIV-positive patients in a Region with an estimated overall number of 
about 3000 HIV-infected patients in treatment or follow up.
Data about all HIV-infected patients >18 years followed at the two centers were retrieved from the 
Database of the Liguria HIV Network (RLH-DB): (www.reteligureHIV.it). The Liguria HIV Network is a 
locally developed online platform that supports the direct connection between medical and laboratory records 
of HIV-infected patients, allowing the automatic and prospective transfer of anonymized data37,38. Each patient 
has an identification code, which is registered in RLH-DB at the engagement (first ambulatory visit for outpa-
tients or first day of hospital stay for inpatients). Safety and precision are granted by the approved use of hospi-
tal anonymized codes. The use of RLH-DB was approved by the Ligurian Ethical Committee. At the moment of 
registration in RHL-DB, patients sign an informed consent form in which they declare if they agree to use their 
clinical data, in anonymous form, for scientific purposes. The study has been performed in accordance with the 
ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and in accordance 
with Italian national laws.
All patients registered in RLH-DB who gave written consent to study participation were considered eli-
gible. The BSI episodes were extrapolated by revision of all positive blood cultures registered in the online 
platform. The number of hospitalizations in PLWHIV was obtained by reviewing discharge diagnostic codes 
of all patients hospitalized during the study period, on the basis of the International Classification of Diseases 
(ICD-9).
BSI was defined as at least one positive blood culture for fungi or bacteria in the setting of a compatible 
clinical disease. For BSI due to the same pathogen (microbial or fungal) at least 30 days between subsequent 
episodes were required to define separate BSI episodes. For BSI due to mycobacteria, multiple positive blood 
cultures, in the same patient, were considered as one single episode. For blood cultures positive for more than 
one pathogen within 48 hours, a single, polimicrobial, episode was considered. For common skin contaminants, 
like coagulase-negative staphylococci, Corynebacterium, Peptostreptococcus, Bacillus and Propionibacterium spe-
cies, at least 2 positive blood cultures were required. For cryptococcosis only cases with positive blood cultures 
were included. For each patient the following information were collected at baseline (at the time of RLH-DB 
registration) or at time of BSI. Baseline information included gender, HBV co-infection (defined by HBsAg pos-
itivity), HCV co-infection (defined by qualitative HCV-RNA positivity), CDC stage (www.CDC.org), CD4+ 
count nadir. Information at time of each BSI included age, CD4+ count, detectable or undetectable (<200 cop-
ies/ml) plasma HIV-RNA, site of acquisition (nosocomial if first positive blood culture after at least 48 hours of 
admission, community-acquired if positive blood culture within the first 48 hours of hospitalization or in case 
of mycobacterial etiology), etiology of BSI, susceptibility pattern of the isolated pathogen (for Candida spp. only 
fluconazole susceptibility). Isolates were identified with the Vitek 2 system (bioMérieux, Marcy l’Etoile, France) 
and/or by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (MALDI 
Biotyper, Bruker Daltonics, Leipzig, Germany, or VitekMS, bioMérieux). The in vitro susceptibility of the isolates 
was assessed with the Vitek 2 system (bioMérieux). Results were interpreted in accordance with the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. Major comorbidities and 
primary causes of hospitalizations were extrapolated by the RLH-DB data and the discharge diagnostic codes 
ICD-9 at each hospitalization. Patients who had CD4+ count <350 cells/µl at the moment of the diagnosis of 
HIV infection were defined as late presenters39. Number of BSI per patient was also collected, as well as the 
total number of hospitalizations in the overall cohort and the number of hospitalizations due to or complicated 
by a BSI. The outcome (survival) was evaluated at 2, 4, 24, 48 weeks after the episode and thereafter till the last 
available follow-up. The computerized systems for patient registration used by the participating centers, allow 
information on the deaths on the entire nation that are notified and updated in real time thanks to connection 
with the national registry office.
statistical analysis. Quantitative data are presented as medians (1st and 3rd quartile) or means (±stand-
ard deviation) and categorical data as absolute numbers and percentages. Quantitative data were compared by 
Mann-Whitney U test, or, when more than two groups were compared, by Kruskal-Wallis test. Categorical var-
iables were compared by chi-square test. Cox regression model was used to assess the impact of the above men-
tioned variables on survival. For the analysis of survival only the etiology of the last episode was considered. The 
impact of the same variables on site of BSI acquisition (community versus hospital acquired) was investigated 
using a generalized linear model, in which BSI episodes within the same subject were assumed as correlated to 
each other. Age was dichotomized according to the best threshold obtained from the receiver operating charac-
teristic (ROC) curve analysis40. Only factors significantly associated with the outcome at univariate analysis were 
included in a multivariate model with a stepwise procedure. P-values < 0.05 were considered statistically signifi-
cant. All analyses were carried out using the SAS software version 9.3 (Institute Inc., Cary, NC, USA).
Data Availability
The dataset used and analyzed during the current study is available from the corresponding author on reasonable 
request.
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